2.2 Study design and population
In this retrospective cohort study, the data of 488 patients
hospitalized with the diagnosis of COVID 19 pneumonia in a tertiary
clinic between October 1, 2020 and November 20, 2020 were
retrospectively analyzed in terms of metabolic syndrome criteria.
Ethical approval of the study was obtained from Umraniye Training and
Research Hospital Ethics Committee dated 20.01.2021 and numbered 1.
Institutional approval was taken for the usage of the patient’s data.
Approval was obtained from all patients for the use of their data for
the scientific article. Patients were hospitalized in the presence of at
least one of the following criteria, in accordance with the COVID-19
guidelines of the Ministry of Health of Turkey8; 1. At
room air, respiratory rate is ≥ 24/min and SpO2 is ≤ 93%. 2. The
presence of at least one of the following: Blood lymphocyte count of
<800 / µl, serum CRP> 10 x upper limit of normal
value, ferritin> 500ng / ml and D-Dimer> 1000
ng / ml, 3. Having comorbidities such as arrhythmia, coronary artery
disease, kidney disease. Inclusion criteria were as follows: Being older
than 18 years of age, a positive COVID 19 PCR result, and having
new-onset infiltration in thorax computed tomography, compatible with
COVID 19 pneumonia. SARS-CoV-2 was detected by next-generation
sequencing or real-time RT-PCR method. Military patients who did not
meet the hospitalization criteria and were followed up for the standard
14 days in isolation (n = 79), patients with lack of data for metabolic
syndrome (n = 202) and patients whose standing waist circumference was
not measured (n = 13) were excluded from the study. A total of 194
patients were included. The patients were divided into two groups as
patients with and without metabolic syndrome (n=93 and 101,
respectively) (Figure 1).